<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644408</url>
  </required_header>
  <id_info>
    <org_study_id>MAIQF</org_study_id>
    <nct_id>NCT02644408</nct_id>
  </id_info>
  <brief_title>Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy</brief_title>
  <official_title>Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Megestrol is a semisynthetic progesterone derivatives, have promote anabolic effects. Can
      improve appetite, weight gain, and improve bone marrow suppression, increase the tolerance
      put, chemotherapy, improve the quality of life, is widely used in tumor radiation and
      chemotherapy of terminally ill patients. But because of its vascular embolization, vaginal
      bleeding, arrhythmia and other serious complications, there is no unified standard.

      The purpose of this study was to evaluate megestrol in esophageal squamous carcinoma radical
      chemoradiation curative effect and side effects, for rational use in the process of radiation
      and chemotherapy megestrol provide guidelines. A total of 210 patients will be accrued from
      China.The primary end point is quality of life (will be evaluated by EORTC QLQ-C30); the
      secondary end point is the pathological response after treatment and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to recruit the patients who were pathologically confirmed with
      esophageal squamous cell carcinoma and performed chemoradiotherapy from the Oct 2014. The
      patients will be divided into two groups.Experimental group：esophageal cancer patients with
      oral megestrol chemoradiation. Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before
      chemoradiotherapy and one week after chemoradiotherapy.

      chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.Control group:
      Esophageal cancer patients with chemoradiation without oral
      megestrol.chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.The
      primary end point is quality of life (will be evaluated by EORTC QLQ-C30); the secondary end
      point is the pathological response after treatment and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patients and the medical professionals who cared for them were unaware of the assigned study regimen.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life (QoF)</measure>
    <time_frame>16 weeks</time_frame>
    <description>evaluated by EORTC QLQ-C30 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathological response</measure>
    <time_frame>16 weeks</time_frame>
    <description>complete response(CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage II Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Megestrol and chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.
chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol（Yining）</intervention_name>
    <description>Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.</description>
    <arm_group_label>Megestrol and chemoradiotherapy</arm_group_label>
    <other_name>Yining</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.</description>
    <arm_group_label>Megestrol and chemoradiotherapy</arm_group_label>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <other_name>radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.</description>
    <arm_group_label>Megestrol and chemoradiotherapy</arm_group_label>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 45-75years old

          -  Histologically proven squamous cell carcinoma of the esophagus the tumor was in
             T2-4N0-2M0

          -  The patients have not received the surgery or chemo-radiotherapy.

          -  Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L,

          -  ALT、AST≤2.5*N,Cr≤1.5*N.

          -  performance status score 0-2

        Exclusion Criteria:

          -  Pregnant, lactating women

          -  Oxaliplatin or fluorouracil Allergy or metabolic disorders

          -  Radiotherapy contraindications

          -  History of organ transplantation

          -  Brain metastasis

          -  The peripheral nervous system disorders

          -  Severe infection

          -  Oral capecitabine who have difficulty with,such as dysphagia,The activities of
             digestive ulcer, Gastrointestinal bleeding

          -  Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high
             blood pressure, diabetes.

          -  Other malignant tumor in recent 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruinuo Jia, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanyou Shan, MD</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinshuai Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiachun Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guoqiang Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhi Yuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshan Feng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Zhuo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Ren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruina Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weijiao Yin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yali Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shegan Gao, MD, PhD</last_name>
    <phone>18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruinuo Jia, MD, PhD</last_name>
    <phone>18537950766</phone>
    <email>jiaruinuo@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shegan gao, doctor</last_name>
      <phone>0379 64811906</phone>
      <email>gsg112258@163.com</email>
    </contact>
    <contact_backup>
      <last_name>tanyou shan, master</last_name>
      <phone>0379 64815350</phone>
      <email>shantanyou@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <reference>
    <citation>Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):287-302. doi: 10.1002/jcsm.12059. Epub 2015 Oct 27. Review.</citation>
    <PMID>26675762</PMID>
  </reference>
  <reference>
    <citation>Ordu C, Pilanci KN, Koksal UI, Okutur K, Saglam S, Tecimer C, Demir G. Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? Asian Pac J Cancer Prev. 2014;15(23):10165-9.</citation>
    <PMID>25556442</PMID>
  </reference>
  <reference>
    <citation>Kanat O. Management of cancer cachexia (reply). Tumori. 2014 Jan-Feb;100(1):e1. doi: 10.1700/1430.15826.</citation>
    <PMID>24675504</PMID>
  </reference>
  <reference>
    <citation>Greig CA, Johns N, Gray C, MacDonald A, Stephens NA, Skipworth RJ, Fallon M, Wall L, Fox GM, Fearon KC. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer. 2014 May;22(5):1269-75. doi: 10.1007/s00520-013-2081-3. Epub 2014 Jan 4.</citation>
    <PMID>24389826</PMID>
  </reference>
  <reference>
    <citation>Hong S, Jeong IG, You D, Lee JL, Hong JH, Ahn H, Kim CS. Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer. J Korean Med Sci. 2013 May;28(5):687-92. doi: 10.3346/jkms.2013.28.5.687. Epub 2013 May 2.</citation>
    <PMID>23678259</PMID>
  </reference>
  <reference>
    <citation>Argilés JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr. 2013 Jun;32(3):319-24. doi: 10.1016/j.clnu.2013.01.004. Epub 2013 Jan 22. Review.</citation>
    <PMID>23395103</PMID>
  </reference>
  <reference>
    <citation>Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012 Apr;31(2):176-82. doi: 10.1016/j.clnu.2011.10.005. Epub 2011 Nov 1.</citation>
    <PMID>22047681</PMID>
  </reference>
  <reference>
    <citation>Gullett NP, Mazurak VC, Hebbar G, Ziegler TR. Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer. 2011 Mar-Apr;35(2):58-90. doi: 10.1016/j.currproblcancer.2011.01.001.</citation>
    <PMID>21420558</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Esophageal Squamous Cancer</keyword>
  <keyword>Megestrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

